Tuberculosis is the most common opportunistic infection and a leading cause of death among patients who infected by Humman Immunodeficiency Virus (HIV) in developing countries. The purpose of this study was to determine the effect of anti-tuberculosis drugs (ATB) on the effectiveness of anti-retroviral (ARV) therapy in HIV-AIDS infected patients.This study was a prospective cohort study conducted at outpatient clinic of Abepura Hospital during April-June 2015. The data were taken from medical records, which include CD4 level, gender, age, education and stage of disease. Statistical analysis was performed using bivariate and multiple regression analysis. A total of 28 subjects was included in this study (7 HIV patients and 21 TB-HIV patients). The results of bivariate analysis showed that there was no significant difference on general characteristics of patients using ARV-ATB and without ATB. Gender, age, occupation, education and the stage of disease did not affect the value of CD4 patients (p>0.005). The result from paired t-test showed that there was no significant difference in the level of CD4 cell, before and after treatment using ARV (p˃0.912), while therapy with ARV-ATB showed significant differences (p˂0.002). In conclusion, this study showed that the combination of ATB and ARV could increase CD4 level up to 72%. Thus, the use of ATB drugs on ARV patients who infected by TB is recommended to reduce disease burden.
Introduction
Acquired Immune Deficiency Syndrome (AIDS) is spectrum of conditions caused by infection of human immunodeficiency virus (HIV). Patients with HIV-AIDS are particularly vulnerable to opportunistic infections due to compromised immune system. The most common opportunistic infection include upper respiratory tract infections, herpes zoster, yeast infections, candidiasis, chronic diarrhea, anemia, cervical cancer, and tuberculosis (TB).
TB is an infectious disease caused by
Mycobacterium tuberculosis which could attack lungs and other organs. 2 TB is still the leading cause of death and illness among people living with HIV in developing countries. HIV infection is a risk factor of having active TB.
3 Construction of a well-established recording and reporting system for TB cases requires private-sector involvement, improvement of recording and reporting for patients' treatment followup, and implementation of electronic-based reporting. 4 Antiretrovirals can suppress viral progression and increase the number CD4 up to 10,000 times in people infected with HIV. Treatment of HIV and TB should be simultaneously effective, as this may affect the prognosis of the disease.
ARV therapy can reduce the risk of TB by 70-90% in HIV-infected patients and can suppress the virus in plasma and normalize CD4 T-cells.
13 CD4 tests in HIV-AIDS patients are usually performed at 2 weeks, 3 months and every 6 months after starting the ARV.
14 Interaction between ATB and ARV such as between rifampicin and efavirenz or nevirapine could decrease bioavailability of ARV. 15 However, limited information was known regarding the clinical effectiveness of the use of combination of ARV-ATB among HIV-AIDS patients infected with TB.
The purpose of this study was to determine the effect of ATB on the effectiveness of ARV in HIV/AIDS patients in Abepura General Hospital of Jayapura.
Methods
This was a prospective observational cohort study, comparing theurapetic effect of two treatment groups, i.e., ARV group and ATB-ARV group during April-June 2015. This research has obtained ethical approval from Abepura General Hospital, Jayapura, with reference number of 008/KM/IV/2015.
The inclusion criteria in this study were: 1. Newly diagnosed HIV-AIDS patients with or without TB. 2. Aged ≥ 18 years old. 3. Had complete medical records. We excluded patients who refused to participate in the study. 
General characteristics of subjects, such as

Results and Discussion
We included 28 subjects in this study, 21 patients received ATB-ARV therapy, while 7 patients only received ARV. General characteristics of the subjects can be found in Table 1 . No significant difference observed between those receiving ATB therapy and those who did not (p> 0.05).
The majority of the subjects in this study were women. A study in Rwanda showed that TB and HIV affected all ages and both sexes. 16 Another study showed that women are more vulnerable than men. [16] [17] [18] The results of a study in Nashville Mexico showed that TB patients tend to occur in men, blacks and heterosexuals. 19, 20 Age is an influential characteristics due to its relation with immune system condition and comorbidities. 21 Therapy with ARV alone did not showed significant difference on CD-4 before and after the treatment (p>0.912). However, the opposite result was observed in ATB-ARV group (p˂0,002). We found that the combination of ATB and ARV did not decrease therapeutic effect of ARV, even significantly increase its effectiveness.
However, these finding should be interpreted with caution since other factors can play a role in the effectiveness of ARV, such as the presence of other comorbities, drugs metabolism, the use of concomitant medication, and adherence to medication.
18
A multivariate analysis of initial and end CD4 value in OAT-ARV group showed significant (p˂0.05) difference with linear regression equation y = 0.798x + 91.144 (r 2 = 72%). In this study, we estimated that interaction between ARV and ATB could be reduced by setting the time of consumption of both drugs. ATB was taken 1 hour before meal, while ARV 1 hour post meal and at night. Drugs interaction could result in increase/ decrease of bioavailability and therapeutic effect of drugs and caused side effects.
20
Several studies showed that the major cause of death in HIV-AIDS patients was due to infection, malignancy, liver disorders, heart problems, respiratory disorders, renal failure, and side-effect related drugs. Another study found that patients with HIV and TB had 15% higher risk of death compared to HIV patients without TB. Combination of TB-HIV treatment is an obligatory step to control disease and reduce disease burden. 2 The results of the study in Rwanda showed that TB-HIV patients who were given appropriate drugs, had improvement in medical conditions (33.3%), with decreasing death rate (20%).
